Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
Department of Geriatric Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China.
BMC Cardiovasc Disord. 2024 Aug 12;24(1):418. doi: 10.1186/s12872-024-04095-4.
Intravitreal injection of anti-vascular endothelial growth factor is considered the first-line treatment for polypoidal choroidal vasculopathy. It has potential risks for circulatory system, which should be particularly carefully evaluated in older patients. In this case study, we aim to discuss the potential impact of this treatment regimen on cardiac health.
This case report describes an elderly patient with no prior history of heart disease who exhibited unexpected heart enlargement and dysfunction. Throughout the patient's hospital stay, various potential causes were investigated, leading to the hypothesis that a 10-year history of intravitreal injections of anti-vascular endothelial growth factor could be related to the observed clinical manifestations. The patient was advised to discontinue this treatment, and after a 2-month follow-up period, there was a gradual improvement in the patient's cardiac structure and function.
This manuscript highlights the importance of conducting cardiac examinations before and after anti-vascular endothelial growth factor treatment, especially for individuals at risk of heart diseases like the elderly. It emphasizes the need to carefully weigh the benefits and risks of treatment regimens to ensure optimal therapeutic outcomes.
玻璃体内注射抗血管内皮生长因子被认为是息肉样脉络膜血管病变的一线治疗方法。它对循环系统有潜在风险，在老年患者中应特别仔细评估。在本病例研究中，我们旨在讨论这种治疗方案对心脏健康的潜在影响。
本病例报告描述了一位无心脏病既往史的老年患者，表现出意外的心脏扩大和功能障碍。在患者住院期间，对各种潜在病因进行了调查，假设 10 年的玻璃体内注射抗血管内皮生长因子治疗可能与观察到的临床表现有关。建议患者停止这种治疗，经过 2 个月的随访，患者的心脏结构和功能逐渐改善。
本手稿强调了在接受抗血管内皮生长因子治疗前后进行心脏检查的重要性，特别是对老年人等有心脏病风险的患者。它强调需要仔细权衡治疗方案的利弊，以确保获得最佳的治疗效果。
